Moreover, five bioactive compounds, namely ginsenoside Rg1, gypenosides, quercetin, ursolic acid, and salidroside, have demonstrated efficacy in ameliorating DC by inhibiting NLRP3 inflammatory vesicles. The gene discussed is NLRP3; the disease is dyskeratosis congenita.